Integrating tumor microenvironment biology with clinical impact: Evolving understanding of therapeutic approaches for MF‑CTCL
Join Dr. Larisa J. Geskin and leading experts for this free, on-demand, interactive, CME-accredited symposium examining the role of the tumor microenvironment (TME) in mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL).
Explore how tumor microenvironment biology influences disease progression and therapeutic response, and how these insights can inform precision-informed treatment selection.
Module Content
Dr. Francine Foss, MD
Dr. Larisa J. Geskin, MD, FAAD
Dr. Christiane Querfeld, MD, PhD
Dr. Sima Rozati, MD, PhD
- Increase knowledge and confidence in interpreting MF-CTCL tumor microenvironment biology, recognizing its influence on disease progression and therapy response, and applying this understanding to guide evidence-based clinical decision-making
- Increase knowledge and confidence in evaluating the cytotoxic and immunomodulatory mechanisms of skin-directed therapies, understanding how these agents modulate the TME to reduce malignant cell burden, enhance antitumor immunity, and guide evidence-based, durable management of MF-CTCL
Introduction
Dr. Larisa J. Geskin (5 minutes)
Understanding the TME in MF-CTCL
Dr. Christiane Querfeld (15 minutes)
Cytotoxic mechanisms of skin-directed therapies
Dr. Sima Rozati (15 minutes)
Targeting tumor and microenvironment in advanced mycosis fungoides/Sezary syndrome
Dr. Francine Foss (15 minutes)
Closing remarks and Q&A
Dr. Larisa J. Geskin (10 minutes)
In support of improving patient care, these activities have been planned and implemented by the Postgraduate Institute for Medicine and Springer Health+ IME. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.
As part of the planning committee, the Postgraduate Institute for Medicine and Springer Health+ IME planners and staff have no financial relationships to disclose.
All relevant financial relationships of the faculty have been mitigated.
In partnership with the United States Cutaneous Lymphoma Consortium (USCLC). This symposium was presented and recorded as part of the USCLC Annual Workshop 2026: Frontiers in Cutaneous Lymphoma: New Technologies, Therapeutics and Future Directions.
Dermapathologists, dermatologists, medical oncologists, oncodermatologists